Request Expert

Expert graduated in Biology at the University of Utrecht, The Netherlands, in 1984. From 1985-89 he was a PhD student at the University of Basel. The research in the field of gene regulation was carried out at the Friedrich Miescher Institute (FMI; Ciba-Geigy) in Basel with an FMI-fellowship. From 1989-91 he worked, with an EMBL-fellowship, as a Postdoctoral fellow at the European Molecular Biology Lab (EMBL) in Heidelberg, Germany in the field of gene expression. From 1991-92 he was Scientific assistant at the University of Munich, Germany in Protein Molecular Biology. In 1992 he started working at Hoffmann-La Roche, Basel, as a Scientist in Biotechnology. In 1994 he became a Global Project Leader in the Drug Development Department and in 1998 Lifecycle Leader in the Primary Care Business Department of Roche Strategic Marketing. In 2004 he moved to Santhera Pharmaceuticals as head of Development and built up a pharmaceutical development group starting from scratch. With this development organisation Santhera achieved its first regulatory license, from project start to approval, in four years. In 2009 Expert became CEO of Eustralis Pharmaceuticals and in parallel founded a consulting agency, Expert Consulting. In his long career in pharmaceutical industry Expert has been involved in all aspects of pharma research, ranging from technical development, preclinical development and clinical development to registration and marketing. During his career he was personally involved in the design of multiple technical, preclinical and clinical development programs. He was in charge of setting up and running multiple clinical trials and and was responsible for various IND and NDA filings in the US, Europe and Japan. Also, as head of a marketing team, he has been involved in launch preparations and drug marketing. Using his background in science, combined with his experience in Development and Marketing Expert has successfully managed multiple Due Diligence procedures for the assessment of potential in-licensing candidates. Expert has experience both in large pharmaceutical as well as in small biotech companies. During his time in large pharma industry, when he additionally gained significant experience in developing drugs for the Japanese market, he was involved in therapeutic areas such as Parkinsons disease, RA, Depression and Anxiety and Congestive Heart Failure. In small biotech he worked in the field of Orphan diseases such as Friedreich's Ataxia, Duchenne Muscular Dystrophy and Leber's Hereditary Optic Neuropathy. He is currently involved in the field of Traumatic Brain Injury (TBI). Overall, most of his pharmaceutical expertise is in the field of Neurology and related areas.

Due Dilligence assessment on a potential In-licensing compound for the biotech company: CardioLynx, based in Basel Switzerland
In the course of this project a set of preclinical and technical study reports were analysed and a assessment report was provided. The report was discussed with the responsible managers of CardioLynx who were able to make a quick decision after a procedure of two weeks.Preparing lectures for the University of Basel in the field of Drug Development. Expert was asked to prepare a set of lectures for the hospital personel involved in clinical studies to create a better understanding for all of the activities required for a new drug approval.Preparing a business plan and an analysis of the development plan for KellSa SA, a company involved in the development of medical devices.